knowledge -WSS

knowledge

author：leisure time 2025-10-01 18:34:30 - browse：338

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Britney Spears to release memoir, 'The Woman In Me,' later this year

Wikipedia

knowledge

WSS

Humans aren't the only ones with an imagination. Rats have it too

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Cuban government calls US nuclear submarine stop a 'provocative escalation'

After Sarepta trial failure, Duchenne families brace for more debate

How to convince healthy people to buy insurance

Digital health funding stays low as a new reality sets in

hotspot

knowledge

focus

The cancer drug shortage isn’t new — and neither are the solutions

What is microchimerism and how does it affect maternal health?

Wildfire smoke exposes gaps in outdoor worker protections

Grail's uphill battle for Medicare to cover its cancer screening test

New air purifier tech could be key to improving indoor air quality

Inari Medical to buy amputation prevention company LimFlow

Malaria cases in Florida and Texas: Here’s what you need to know

Travis Kelce and the trap of celebrity vaccine endorsements

Affirmative action in medical school literally saved lives

Kidney transplant patients stopped immunosuppressants in trial

entertainment

DeepMind touts AlphaFold's new skills as protein folding AI models face off

A Greenpeace activist is fined for crash

Bill would allow buprenorphine prescription for addiction via telehealth

Gene therapy’s promise and the high cost of hope

Explaining an after

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Wikipedia

knowledge

knowledge

knowledge